Related Experiment Video
Updated: Jul 13, 2026
08:32
A Pre-Clinical Model of Synovitis Using Ex vivo Human Synovial Tissue with Preserved Function and Architecture
Published on: March 20, 2026
[Seronegative spondylarthropathy: variable manifestations, common characteristics]
A W A M van Rijthoven1, J W G Jacobs
1Universitair Medisch Centrum Utrecht, afd. Reumatologie en Klinische Immunologie, F02.127, Postbus 85.500, 3508 GA Utrecht. a.vanrijthoven@umcutrecht.nl
Nederlands Tijdschrift Voor Geneeskunde
|August 3, 2007
Summary
Undifferentiated spondylarthropathy can be challenging to treat. TNFalpha-blocking agents like adalimumab show promise in managing severe cases and preventing long-term damage, unlike conventional therapies.
Area of Science:
- Rheumatology
- Immunology
- Genetics
Background:
- Spondylarthropathy encompasses chronic, progressive inflammatory conditions often associated with HLA-B27.
- Features include oligoarthritis, enthesitis, tendinitis, bursitis, and uveitis, posing diagnostic challenges.
Observation:
- Two patients with undifferentiated spondylarthropathy presented with varying symptoms and disease histories.
- One patient's peripheral arthritis responded to methotrexate, but she later developed ankylosing spondylitis.
- The other patient's refractory spondylarthropathy improved significantly with adalimumab, a TNFalpha-blocking agent.
Findings:
- Conventional disease-modifying antirheumatic drugs (DMARDs) are often ineffective against axial inflammation in spondylarthropathy.
- TNFalpha-blocking agents demonstrate superior efficacy in inhibiting axial inflammation compared to conventional DMARDs.
- Adalimumab provided a robust therapeutic response in a patient with refractory undifferentiated spondylarthropathy.
Implications:
- Early intervention with TNFalpha-blocking agents may be crucial for preventing structural damage and functional disability in severe spondylarthropathy.
- These findings highlight the potential of targeted biologic therapies in managing complex spondylarthropathy cases.
- Further research into the role of TNFalpha inhibitors in early-stage and severe spondylarthropathy is warranted.
Related Concept Videos
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
01:27Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
01:25Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
01:19Pericarditis II: Clinical Features and Diagnostic Tests
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...